Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

recurrent Ewing Sarcoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Recurrent Ewing Sarcoma

Broader topic: Ewing Sarcoma

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of Recurrent Ewing Sarcoma

    Study evidence for this setting

    10 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00520936 · Source cited / selected · Scope: unclear

    A Study of Pemetrexed in Children With Recurrent Cancer

    3 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT00831844 · Registry condition search · Scope: unclear

    Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

    1 outcome links · 10 safety-group records · 0 quality-of-life measures

    →

    NCT01586104 · Registry condition search · Scope: unclear

    Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases

    3 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT02162732 · Registry condition search · Scope: unclear

    Molecular-Guided Therapy for Childhood Cancer

    4 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03213665 · Source cited / selected · Scope: unclear

    Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03213678 · Registry condition search · Scope: unclear

    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATC

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03245450 · Source cited / selected · Scope: unclear

    Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

    6 outcome links · 7 safety-group records · 0 quality-of-life measures

    →

    NCT03441360 · Source cited / selected · Scope: unclear

    Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sar

    6 outcome links · 3 safety-group records · 0 quality-of-life measures

    →

    NCT03698994 · Registry condition search · Scope: unclear

    Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT04730349 · Registry condition search · Scope: unclear

    A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice